Lv1
70 积分 2021-12-06 加入
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
6天前
已完结
Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial
7天前
已完结
New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria
7天前
已完结
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
9天前
已完结
Evolving therapeutic landscape of advanced hepatocellular carcinoma
9天前
已完结
Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations
9天前
已完结
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population
11天前
已完结
Neoplasm risk in individuals with neurofibromatosis 1 – a Danish nationwide cohort study with long-term follow-up
12天前
已关闭
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
16天前
已完结
First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study
27天前
已完结
皖公网安备34019202002308
